AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter. | TechCrunch
AI's impact in science is exemplified by DeepMind's protein structure predictions, but characterizing treatment candidates remains a significant challenge.
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
The GLP-1 revolution is driving biopharma M&A strategies, with companies like Viking Therapeutics and Structure Therapeutics as prime acquisition targets.
Major pharmaceutical company to cut nearly 250 Massachusetts jobs
The layoffs are part of a transformation plan approved by Takeda's board on March 25, expected to generate more than 200 billion Japanese yen in annualized savings by fiscal 2028, or about $1.25 billion.